Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Status and Forecast 2020-2026
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.
Market Analysis and Insights: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
In 2019, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was US$ 274.3 million and it is expected to reach US$ 439.8 million by the end of 2026, with a CAGR of 6.9% during 2021-2026.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Scope and Market Size
Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented into Riluzole, Edaravone (Radicava), Other, etc.
Segment by Application, the Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented into Hospital, Drugs Store, Other, etc.
Regional and Country-level Analysis
The Amyotrophic Lateral Sclerosis (ALS) Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Amyotrophic Lateral Sclerosis (ALS) Treatment market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.
Amyotrophic Lateral Sclerosis (ALS) Treatment market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Amyotrophic Lateral Sclerosis (ALS) Treatment business, the date to enter into the Amyotrophic Lateral Sclerosis (ALS) Treatment market, Amyotrophic Lateral Sclerosis (ALS) Treatment product introduction, recent developments, etc.
The major vendors include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, etc.
This report focuses on the global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Riluzole
Edaravone (Radicava)
Other
Hospital
Drugs Store
Other
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
To analyze global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players.
To present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Amyotrophic Lateral Sclerosis (ALS) Treatment are as follows:
History Year: 2015-2019
2019
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.
Market Analysis and Insights: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
In 2019, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was US$ 274.3 million and it is expected to reach US$ 439.8 million by the end of 2026, with a CAGR of 6.9% during 2021-2026.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Scope and Market Size
Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented into Riluzole, Edaravone (Radicava), Other, etc.
Segment by Application, the Amyotrophic Lateral Sclerosis (ALS) Treatment market is segmented into Hospital, Drugs Store, Other, etc.
Regional and Country-level Analysis
The Amyotrophic Lateral Sclerosis (ALS) Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Amyotrophic Lateral Sclerosis (ALS) Treatment market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.
Competitive Landscape
and Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share AnalysisAmyotrophic Lateral Sclerosis (ALS) Treatment market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Amyotrophic Lateral Sclerosis (ALS) Treatment business, the date to enter into the Amyotrophic Lateral Sclerosis (ALS) Treatment market, Amyotrophic Lateral Sclerosis (ALS) Treatment product introduction, recent developments, etc.
The major vendors include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, etc.
This report focuses on the global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Market segment by Type, the product can be split into
Riluzole
Edaravone (Radicava)
Other
Market segment by Application, split into
Hospital
Drugs Store
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players.
To present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Amyotrophic Lateral Sclerosis (ALS) Treatment are as follows:
History Year: 2015-2019
Base Year:
2019Estimated Year:
2020Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
